DoD’s Fluorspar Solicitation Confirms What We Knew: Domestic Suppliers Like Ares Are Critical
We called it. The Defense Logistics Agency’s (DLA) now-closed $250 million solicitation (SP8000-25-R-0020) for acid-grade fluorspar isn’t just another procurement—it’s a neon sign that the U.S. is finally waking up to its critical minerals problem. Since its inception, Endeavour has been highlighting the risks of relying on foreign fluorspar, a linchpin for defense manufacturing from […]
Investors Eye Gold and Silver, but Palladium’s Surge is Demanding Attention
Gold and silver may be dominating headlines with record highs, but palladium is quietly staging a comeback. Prices are up more than 34% this year, driven by industrial demand and tightening supply, positioning the metal as one to watch.
Trilogy Metals Shares Surge Over 200% After U.S. Takes 10% Stake
Trilogy Metals shares skyrocketed after the U.S. government announced a $35.6 million investment, signaling a renewed federal commitment to securing America’s critical mineral supply chains and advancing domestic resource development in Alaska.
Pharma Stocks Split as Trump Unveils 100% Drug Tariff
Trump’s 100% tariff on foreign-made branded drugs has shaken markets, with analysts warning the impact won’t be evenly felt.
Should You Invest in Gold? 7 Experts Weigh In
Gold futures have surged past $3,700 an ounce, prompting experts to weigh in on whether investors should jump in—or has that ship sailed?
Nvidia to Invest $100B in OpenAI, Cementing Partnership
Nvidia and OpenAI are joining forces in a landmark $100 billion partnership, combining Nvidia’s GPU leadership with OpenAI’s AI development to shape the next era of artificial intelligence.
Buy, Sell, or Hold: Hims & Hers Stock Surges 64%
The past six months have been a windfall for Hims & Hers Health’s shareholders as the stock surged 64%. Is now the right time to buy HIMS? Or is this rally more about investor enthusiasm than fundamentals?
This Biotech’s Phase 3 Results Could Be a Game-Changer for Investors
The next few weeks for aTyr Pharma will reveal a great deal about this company’s future. aTyr Pharma is set to transform treatment for pulmonary sarcoidosis and unlock blockbuster potential. Is the stock a good investment right now? Let’s find out.
Top Tip: Mining Multibagger, Ready to Run
U.S. junior critical mineral miner, ARES STRATEGIC MINING (CSE: ARS | FRA: N8I1 | OTC: ARSMF), is about to have its long-awaited Cinderella moment. For 5 years now, ARES has owned the only permitted fluorspar mine in the U.S. out of Delta, Utah. They’ve been drilling, fund-raising and constructing facilities, all the while hoping someone […]
3 U.S. Energy Producers to Watch Amid Record Output
Record-breaking U.S. oil output is having a big impact on the market. Here’s where investors could benefit from the surge.
English 
German